The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III, randomized, double-blind, multicenter, active control study of fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving cisplatin-based highly emetogenic chemotherapy (HEC): CONSOLE.
 
Yoshimasa Shiraishi
Honoraria - AstraZeneca Japan; Lilly Japan
Research Funding - Chugai Pharma; Chugai Pharma
 
Akito Hata
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); MSD (Inst)
 
Naoki Inui
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD K.K (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Morihito Okada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien; CSL Behring; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Masahiro Morise
Speakers' Bureau - AstraZeneca; Chugai/Roche; Lilly; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai/Roche (Inst); Kissei Pharmaceutical (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Kohei Akiyoshi
No Relationships to Disclose
 
Masayuki Takeda
Speakers' Bureau - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical
 
Yasutaka Watanabe
No Relationships to Disclose
 
Shunichi Sugawara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Naofumi Shinagawa
Research Funding - Olympus (Inst)
 
Kaoru Kubota
Consulting or Advisory Role - Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst)
 
Toshiaki Saeki
Research Funding - Eisai (Inst); Taiho Pharmaceutical (Inst)
 
Tomohide Tamura
Honoraria - Boehringer Ingelheim; Chugai Pharma; CMIC; Lilly; MSD; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical